市場調查報告書

生化防禦的全球市場:至2027年的分析與預測

Biodefense Market to 2027 - Global Analysis and Forecasts by Product (Anthrax, Small Pox, Botulism, Radiation/Nuclear, and Others) and Geography

出版商 The Insight Partners 商品編碼 932080
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
生化防禦的全球市場:至2027年的分析與預測 Biodefense Market to 2027 - Global Analysis and Forecasts by Product (Anthrax, Small Pox, Botulism, Radiation/Nuclear, and Others) and Geography
出版日期: 2020年03月31日內容資訊: 英文 136 Pages
簡介

全球生化防禦市場在2019年估算為41億824萬美元,預計2027年將達到83億5074萬美元,從2020年到2027年的年複合成長率將為9.4%。帶動這個市場成長的主要原因,是政府的積極推動,自然發生的爆發增加,生物武器和核武裝ICBM的威脅的增加等。可是,開發中國家的政府的研究開發資金少,預計抑制在預測期間內的市場成長。

本報告提供全球生化防禦市場的相關調查,市場概要,各產品及各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,市場佔有率,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 生化防禦市場:重要的要點

第3章 調查手法

第4章 生化防禦的市場形勢

  • 概況
  • PEST分析
  • 專家的意見

第5章 全球生化防禦市場:產業動態

  • 主要原因
  • 主要的市場阻礙因素
  • 主要的市場機會
  • 今後趨勢
  • 影響分析

第6章 全球生化防禦市場分析

  • 全球生化防禦市場收益預測與分析
  • 全球生物武器國防市場的預測與分析
  • 主要企業的市場定位

第7章 生化防禦市場分析:各產品

  • 概況
  • 生化防禦市場收益佔有率,各產品
  • 炭疽菌
  • 天花
  • 肉毒桿菌
  • 放射性核能/核
  • 其他

第8章 生化防禦市場:地區分析

    • 概況
    • 北美的生化防禦市場:收益及預測
    • 北美的生化防禦市場:各產品
    • 北美的生化防禦市場:各國
    • 美國的生化防禦市場:收益及預測
    • 加拿大的生化防禦市場:收益及預測
    • 墨西哥的生化防禦市場:收益及預測
  • 歐洲的生化防禦市場
    • 概況
    • 歐洲的生化防禦市場:收益及預測
    • 歐洲的生化防禦市場:各產品
    • 歐洲的生化防禦市場:各國
    • 德國的生化防禦市場:收益及預測
    • 英國的生化防禦市場:收益及預測
    • 法國的生化防禦市場:收益及預測
    • 西班牙的生化防禦市場:收益及預測
    • 義大利的生化防禦市場:收益及預測
  • 亞太地區的生化防禦市場
    • 概況
    • 亞太地區的生化防禦市場:收益及預測
    • 亞太地區的生化防禦市場:各產品
    • 亞太地區的生化防禦市場:各國
    • 中國的生化防禦市場:收益及預測
    • 日本的生化防禦市場:收益及預測
    • 印度的生化防禦市場:收益及預測
    • 韓國的生化防禦市場:收益及預測
    • 澳洲的生化防禦市場:收益及預測
  • 中南美的生化防禦市場
    • 概況
    • 中南美的生化防禦市場:收益及預測
    • 中南美的生化防禦市場:各產品
    • 中南美的生化防禦市場:各國
    • 巴西的生化防禦市場:收益及預測
    • 阿根廷的生化防禦市場:收益及預測

第9章 全球生化防禦市場上COVID-19大流行病的影響

  • 北美:COVID-19大流行病的影響評估
  • 歐洲:COVID-19大流行病的影響評估
  • 亞太地區:COVID-19大流行病的影響評估
  • 中東、非洲地區:COVID-19大流行病的影響評估
  • 南美:COVID-19大流行病的影響評估

第10章 生化防禦市場: 產業形勢

  • 概況
  • 生化防禦市場上成長策略
  • 無機的成長策略
  • 內部成長策略

第11章 企業簡介

  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • pluristem

第12章 附錄

目錄
Product Code: TIPRE00005377

The global biodefense market was valued at US$ 4,108.24 million in 2019 and is projected to reach US$ 8,350.74 million in 2027; it is expected to grow at a CAGR of 9.4% from 2020 to 2027.

Favorable government initiatives, increase in the number of naturally occurring outbreaks, and increasing threat of biological weapons and nuclear armed ICBM are some of the major factors driving the growth of global biodefense market. However, low government R&D funding in developing and underdeveloped economies is expected to restraint the growth of the market during the forecast period.

Disease outbreaks are usually caused by an infection transmitted through person-to-person contact, animal-to-person contact, or from the environment. The emergence of infectious diseases has increased significantly during the recent years. The World Health Organization warned in its 2007 report that infectious diseases are emerging at a high rate across the world. Since 1970, about 40 infectious diseases have been discovered, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, zika, and most recently, COVID-19. According to the estimation of Centers of Disease Control and Prevention (CDC,) in the US, nearly 30 million people suffered from influenza between 2016 and 2017. Biodefense techniques, such as vaccinations against influenza help reduce the illness by 17% and medical visits and hospitalizations by 18% and 19%, respectively. The growing prevalence of Ebola and Zika virus infections is also likely to contribute to the market growth. For instance, according to the CDC, as of November 2015, over 28,000 Ebola virus cases and more than 3,800 deaths because of Ebola virus were reported in Guinea. Additionally, due to coronavirus outbreak, more than 210,000 cases have been reported to WHO, and more than 9,000 people have lost their lives till March 20, 2020. Further, on March 18, 2020 Emergent BioSolutions signed a development and manufacturing agreement with Vaxart for their oral vaccine experiment on infected candidate for Coronavirus Disease. The growing prevalence of infectious diseases, such as coronavirus, Ebola, and zika virus is likely to boost the investments in the field of biodefense, thereby driving the market growth.

The global biodefense market is segmented into product and geography. Based on product, the biodefense market is segmented into anthrax, small pox, botulism, radiation/nuclear and others. The anthrax segment accounted for the largest market share in 2019. The anthrax segment is expected to continue its dominance during the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives, such as BioShield Act, Biomedical Advanced Research and Development Authority (BARDA), and the Joint Program Executive Office for Chemical & Biological Defense.

Food and Drug Administration, World Health Organization (WHO), Organisation for Economic Co-operation and Development, Socio-Economic Contribution of the European Cosmetics Industry (SECECI), and Emirates Standardization and Meteorological Authority (ESMA) are some of the essential secondary sources included in the report.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the biodefense market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Biodefense Market - By Product
    • 1.3.2 Global Biodefense Market - By Geography

2. Biodefense Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Biodefense - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
    • 4.2.4 Middle East & Africa
    • 4.2.5 South and Central America
  • 4.3 Expert Opinion

5. Global Biodefense Market - Industry Dynamics

  • 5.1 Key Drivers
    • 5.1.1 Presence of Favourable Government Initiatives
    • 5.1.2 Increase in the Number of Naturally Occurring Outbreaks
    • 5.1.3 Increasing Threat of Biological Weapons and Nuclear Armed ICBM
  • 5.2 Key Market Restraints
    • 5.2.1 Low R&D Funding by Government in Developing and Underdeveloped Economies
  • 5.3 Key Market Opportunities
    • 5.3.1 Increased Adoption of Technologies
  • 5.4 Future Trends
    • 5.4.1 Predictive Analytics to Reshape Biodefense Market
  • 5.5 Impact Analysis

6. Biodefense Market - Global Analysis

  • 6.1 Global Biodefense Market Revenue Forecast And Analysis
  • 6.2 Global Biodefense Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Biodefense Market Analysis - By Product

  • 7.1 Overview
  • 7.2 Biodefense Market Revenue Share, by Product (2019 and 2027)
  • 7.1 Anthrax
    • 7.1.1 Overview
    • 7.1.2 Anthrax: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.2 Small pox
    • 7.2.1 Overview
    • 7.2.2 Small pox: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.3 Botulism
    • 7.3.1 Overview
    • 7.3.2 Botulism: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.4 Radiation/Nuclear
    • 7.4.1 Overview
    • 7.4.2 Radiation/Nuclear: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)

8. Biodefense Market - Geographic Analysis

    • 8.1.1 Overview
    • 8.1.2 North America: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
    • 8.1.3 North America: Biodefense Market, by Product, 2018-2027 (USD Million)
    • 8.1.4 North America: Biodefense Market, by Country, 2019 & 2027 (%)
    • 8.1.5 US: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.1.5.1 US: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.1.5.2 US: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.1.6 Canada: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.1.6.1 Canada: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.1.6.2 Canada: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.1.7 Mexico: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.1.7.1 Mexico: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.1.7.2 Mexico: Biodefense Market, by Product Type, 2018-2027 (USD Million)
  • 8.2 Europe: Biodefense Market
    • 8.2.1 Overview
    • 8.2.2 Europe: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
    • 8.2.3 Europe: Biodefense Market, by Product, 2018-2027 (USD Million)
    • 8.2.4 Europe: Biodefense Market, by Country, 2018 & 2027 (%)
    • 8.2.5 Germany: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.5.1 Germany: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.5.2 Germany: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.2.6 UK: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.6.1 UK: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.6.2 UK: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.2.7 France: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.7.1 France: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.7.2 France: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.2.8 Spain: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.8.1 Spain: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.8.2 Spain: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.2.9 Italy: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.9.1 Italy: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.2.9.2 Italy: Biodefense Market, by Product Type, 2018-2027 (USD Million)
  • 8.3 Asia Pacific: Biodefense Market
    • 8.3.1 Overview
    • 8.3.2 Asia Pacific: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
    • 8.3.3 Asia Pacific: Biodefense Market, by Product, 2018-2027 (USD Million)
    • 8.3.4 Asia Pacific: Biodefense Market, by Country, 2018 & 2027 (%)
    • 8.3.5 China: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.5.1 China: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.5.2 China: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.3.6 Japan: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.6.1 Japan: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.6.2 Japan: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.3.7 India: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.7.1 India: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.7.2 India: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.3.8 South Korea: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.8.1 South Korea: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.8.2 South Korea: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.3.9 Australia: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.9.1 Australia: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.3.9.2 Australia: Biodefense Market, by Product Type, 2018-2027 (USD Million)
  • 8.4 South and Central America: Biodefense Market
    • 8.4.1 Overview
    • 8.4.2 South and Central America: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
    • 8.4.3 South and Central America: Biodefense Market, by Product, 2018-2027 (USD Million)
    • 8.4.4 South and Central America: Biodefense Market, by Country, 2018 & 2027 (%)
    • 8.4.5 Brazil: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.4.5.1 Brazil: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.4.5.2 Brazil: Biodefense Market, by Product Type, 2018-2027 (USD Million)
    • 8.4.6 Argentina: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.4.6.1 Argentina: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
      • 8.4.6.2 Argentina: Biodefense Market, by Product Type, 2018-2027 (USD Million)

9. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BIODEFENSE MARKET

  • 9.1 North America: Impact assessment of COVID-19 Pandemic
  • 9.2 Europe: Impact assessment of COVID-19 Pandemic
  • 9.3 Asia-Pacific: Impact assessment of COVID-19 Pandemic
  • 9.4 MEA: Impact assessment of COVID-19 Pandemic
  • 9.5 SAM: Impact assessment of COVID-19 Pandemic

10. Biodefence Market -Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in The Biodefence Market, 2016-2020
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. COMPANY PROFILES

  • 11.1 Bavarian Nordic
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Alnylam Pharmaceuticals, Inc.
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 SIGA Technologies
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Emergent BioSolutions Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Cleveland Bio Labs
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Dynavax Technologies
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Elusys Therapeutics, Inc.
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Soligenix
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Altimmune
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 pluristem
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

LIST OF TABLES

  • Table 1. North America Biodefense Market, by Product- Revenue and Forecast to 2027 (USD Million)
  • Table 2. US Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 3. Canada Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 4. Mexico Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 5. Europe Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 6. Germany Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 7. UK Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 8. France Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 9. Spain Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 10. Itlay Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 11. Asia Pacific Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 12. China Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 13. Japan Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 14. India Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 15. South Korea Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 16. Australia Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 17. South and Central America Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 18. Brazil Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 19. Argentina Biodefense Market, by Product - Revenue and Forecast to 2027 (USD Million)
  • Table 20. Recent Inorganic Growth Strategies In The Biodefence Market
  • Table 21. Recent Organic Growth Strategies In The Biodefence Market
  • Table 22. Glossary of Terms, Skin aesthetic devices market

LIST OF FIGURES

  • Figure 1. Biodefense Market Segmentation
  • Figure 2. Biodefense Segmentation, By Region
  • Figure 3. Global Biodefense Market Overview
  • Figure 4. The Anthrax Segment Held Largest Share Of Product Segment In Biodefense Market
  • Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period
  • Figure 6. Global Biodefense Market, By Geography (US$ Million)
  • Figure 7. Global Biodefense Market- Leading Country Markets (US$ Million)
  • Figure 8. Global Biodefense Market, Industry Landscape
  • Figure 9. North America PEST Analysis
  • Figure 10. Europe: PEST Analysis
  • Figure 11. Asia Pacific PEST Analysis
  • Figure 12. Middle East & Africa PEST Analysis
  • Figure 13. South and Central America PEST Analysis
  • Figure 14. Global Biodefense Market - Revenue Forecast And Analysis - 2019- 2027
  • Figure 15. Global Biodefense Market - By Geography Forecast And Analysis - 2019- 2027
  • Figure 16. Market Positioning Of Key Players In Global Biodefense Market
  • Figure 17. Biodefense Market Revenue Share, by Product (2019 and 2027)
  • Figure 18. Anthrax: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 19. Small pox: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 20. Botulism: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 21. Radiation/Nuclear: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 22. Others: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 23. North America: Biodefense Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 24. North America Biodefense Market Revenue and Forecast to 2027 (USD Million)
  • Figure 25. North America: Biodefense Market, by Country, 2019 & 2027 (%)
  • Figure 26. US: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 27. Canada: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 28. Mexico: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 29. Europe: Biodefense Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 30. Europe Biodefense Market Revenue and Forecast to 2027 (USD Million)
  • Figure 31. Europe: Biodefense Market, by Country, 2018 & 2027 (%)
  • Figure 32. Germany: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 33. UK: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 34. France: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 35. Spain: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 36. Italy: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 37. Asia Pacific: Biodefense Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 38. Asia Pacific Biodefense Market Revenue and Forecast to 2027 (USD Million)
  • Figure 39. China: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 40. Japan: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 41. India: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 42. South Korea: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 43. Australia: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 44. South and Central America: Biodefense Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 45. South and Central America Biodefense Market Revenue and Forecast to 2027 (USD Million)
  • Figure 46. South and Central America: Biodefense Market, by Country, 2018 & 2027 (%)
  • Figure 47. Brazil: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 48. Argentina: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 49. Impact of COVID-19 Pandemic In North American Country Markets
  • Figure 50. Impact of COVID-19 Pandemic In European Country Markets
  • Figure 51. Impact of COVID-19 Pandemic In Asia Pacifician Country Markets
  • Figure 52. Impact of COVID-19 Pandemic In Middle East & African Country Markets
  • Figure 53. Impact of COVID-19 Pandemic In SCAM Countries Markets
  • Figure 54. Growth Strategies in the Biodefence Market, 2016-2020